The role of aspirin in the secondary prevention of ischaemic events is being challenged.
CAPRIE, a blinded multicenter randomized trial of over 19000 patients followed for 1–3
years, assessed the effect of clopidogrel in the secondary prevention of major vascular
events. Patients with a recent myocardial infarction, stroke or peripheral arterial disease
were randomized to treatment with clopidogrel or aspirin. Clopidogrel was associated with a
statistically significant, overall 8.7%, relative reduction in the risk of ischaemic events, but the …